BrightSpring Health Services, Inc. beat analyst estimates for the second quarter of 2026 and raised its full-year financial guidance [1, 2, 3].
The results signal a period of aggressive expansion for the company, driven by a surge in home-health demand and pharmacy profitability. This growth allows the firm to tighten its financial leverage while increasing its earnings projections for the remainder of the year.
For the second quarter, BrightSpring reported an adjusted earnings per share (EPS) of $0.45 [2]. This figure surpassed the Zacks Consensus EPS estimate of $0.37 [2]. Reports on the exact percentage of the earnings beat vary between 13% and 21.6% [2, 4].
Revenue for the quarter saw a 23% increase year-over-year [1]. Other reports indicate the company beat revenue estimates by 5.7% [4]. The company said these gains were due to strong performance in its specialty sectors, most notably a 54% surge in home-health volume [4, 5].
Pharmacy operations also contributed to the bottom line with a 28% jump in profit per prescription [4, 5]. These operational wins prompted the company to increase its full-year 2026 revenue and adjusted EBITDA guidance [3, 5].
BrightSpring now projects an adjusted EBITDA for 2026 between $820 million and $845 million [1]. Additionally, the company said it is targeting a leverage ratio below 2x for the year [1].
The company's financial trajectory remains tied to the scaling of its specialty services. By increasing volume in home health and improving margins in pharmacy, the company has shifted its 2026 outlook upward [5, 6].
“Revenue for the quarter saw a 23% increase year-over-year”
BrightSpring's ability to simultaneously grow revenue and lower its leverage ratio suggests a transition from a growth-at-all-costs phase to a more sustainable, high-margin operational model. The significant jump in home-health volume indicates a strong market shift toward decentralized care, which the company is successfully capturing to drive its EBITDA projections higher.
